Literature DB >> 1325611

Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations.

P G McNally1, J Feehally.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325611

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  11 in total

Review 1.  Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Authors:  Daniel J Salzberg
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 2.  Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale.

Authors:  Moro O Salifu; Fasika Tedla; Serhat Aytug; Amir Hayat; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 3.  Chronic rejection and late renal allograft dysfunction.

Authors:  J Laine; C Holmberg; P Häyry
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

4.  Vascular mechanisms of cyclosporin-induced hypertension in the rat.

Authors:  J B Roullet; H Xue; D A McCarron; S Holcomb; W M Bennett
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

5.  Effects of a selective adenosine A1 receptor antagonist on the development of cyclosporin nephrotoxicity.

Authors:  V S Balakrishnan; C J von Ruhland; D F Griffiths; G A Coles; J D Williams
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome.

Authors:  S A Hulton; L Jadresic; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

Review 8.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

9.  Hypertension in chronic kidney disease: navigating the evidence.

Authors:  F M Tedla; A Brar; R Browne; C Brown
Journal:  Int J Hypertens       Date:  2011-05-24       Impact factor: 2.420

Review 10.  Hypertension after renal transplant.

Authors:  Fasika Tedla; Rick Hayashi; Samy I McFarlane; Moro O Salifu
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.